May 8 P&P Quick Takes: FTC, Part D, Orange/Purple Book, FDA, Cornyn/Blumenthal

FTC objects to FDA's latest guidance on biologic naming
The Federal Trade Commission again advised that FDA drop its biologic suffix naming convention because it could diminish biosimilar competition, bolstering arguments from some biosimilars

Read the full 335 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE